Progress in Neurotherapeutics and Neuropsychopharmacology ( Vol. 1 )

di Cummings • 2006 • dettagli prodotto

non più pubblicato

€ 94,62

Paga gli acquisti tra 30€ e 2.000€ in 3 rate
senza interessi. Scopri di più

DESCRIZIONE

Volumes in this series provide readers with updates of recent clinical trial results in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses. It is an essential update of recent trials in all aspects of the management of neurological and neuropsychiatric disorders.Table of Contents Preface J. L. CummingsIntroduction to Neurotherapeutics and Neuropharmacology J. L. Cummings1. Rivastigmine in the treatment of dementia associated with Parkinson's disease: a randomized, double-blind, placebo-controlled study S. Tekin and R. Lane2. Modafinil for the treatment of fatigue in multiple sclerosis B. Stankoff, C. Lubetzki and M. Clanet3. Radiotherapy with concurrent and adjuvant temozolomide: a new standard of care for glioblastoma multiform W. P. Mason, R. O. Mirimanoff, and R Stupp4. Treating migraine attacks ASAP: concept and methodological issues N. J. Wiendels and M. D. Ferrari5. Early phase trials of minocycline in amyotropic lateral sclerosis P. H. Gordon, J. Choi, D. H. Moore and R. G. Miller6. Creatine as a potential treatment for amyotrophic lateral sclerosis J. M. Shefner7. AVP-923 as a novel treatment for pseudobulbar affect ALS L. E. Pope8. Liquid fluoxetine vs. placebo for repetitive behaviors in childhood autism E. Hollander, E. Swanson, E. Anagnostou, A. Phillips, W. Chaplin and S. Wasserman9. Testing multiple novel mechanisms for treating schizophrenia in a single trial H. Y. Meltzer10. Selegiline in the treatment of negative symptoms of schizophrenia A. Lin and A. Bodkin11. Analysis of the cognitive enhancing effects of modafinil in schizophrenia D. C. Turner and B. J. Sahakian12. Efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatient with schizophrenia or schizoaffective disorder: results of a double-blind, 6-week study, with a 6-month, double-blind, continuation phase G. M. Simpson, A. Loebel, L. Warrington and R. Yang